Form 4: Marinus Pharmaceuticals' Chief Medical Officer Receives Stock Options and Restricted Stock Units

Chief Medical Officer of Marinus Pharmaceuticals, Joseph Hulihan, reports acquisition of stock options and restricted stock units.

Summary

• Joseph Hulihan, Chief Medical Officer of Marinus Pharmaceuticals, reported changes in beneficial ownership on June 18, 2024.
• Hulihan acquired 10,918 shares of common stock through restricted stock units (RSUs) and 49,125 stock options.
• The RSUs vest in full on July 15, 2025, contingent upon continued service with Marinus Pharmaceuticals, and each RSU represents the right to receive one share of common stock.
• The stock options, with an exercise price of $1.40, also vest fully on July 15, 2025, subject to continued service, and expire on June 18, 2034.
• Following these transactions, Hulihan beneficially owns 77,553 shares of common stock and 49,125 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices, aligning management interests with shareholders.

Positives

• The grant of RSUs and stock options to the Chief Medical Officer aligns his interests with the long-term success of Marinus Pharmaceuticals.
• The vesting schedule, contingent on continued service, incentivizes the executive to remain with the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the granted securities.

Industry Context

This type of equity grant is a common practice in the pharmaceutical industry to incentivize and retain key executives.

Comparison to Industry Standards

• Equity compensation for CMOs in similarly sized pharmaceutical companies typically includes a mix of stock options and restricted stock units.
• Vesting schedules of one to three years are standard to ensure continued service and alignment with company goals.
• The specific amounts and terms would be benchmarked against peer companies in the biopharmaceutical sector.

Stakeholder Impact

• The equity grants aim to align the executive's interests with those of the shareholders, potentially driving long-term value creation.
• Employees may view the grants positively as a sign of investment in leadership.

Key Dates

Keywords

Marinus Pharmaceuticals, MRNS, Form 4, Beneficial Ownership, Joseph Hulihan, Chief Medical Officer, Stock Options, Restricted Stock Units, RSUs